Guest Editors
Dr. Wojciech Czyżewski
Email: wojciech.w.czyzewski@gmail.com
Affiliation: Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Homepage:
Research Interests: neuro-oncology, pituitary and sellar tumors (PitNETs), astrocytic tumors, molecular biomarkers, tumor microenvironment, precision and translational medicine, experimental models, treatment response and resistance mechanisms
Dr. Jakub Litak
Email: jakub.litak@gmail.com
Affiliation: Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland
Homepage:
Research Interests: brain injury, lymphoma, multiple myeloma, hematologic diseases, stem cell transplantation
Assist. Prof. Grzegorz Turek
Email: turek.grz@gmail.com
Affiliation: Department of Neurosurgery, Bródnowski Masovian Hospital, Warsaw, Poland
Homepage:
Research Interests: schwann cell biology and pathogenesis of vestibular schwannomas, tumor–nerve interface and cranial nerve preservation, radiosensitivity and molecular predictors of therapeutic response
Dr. Mateusz Bilski
Email: bilskimat@gmail.com
Affiliation: Affidea Nu-med Center of Oncological Diagnostics and Therapy, Zamosc, Poland
Homepage:
Research Interests: radiation oncology, radiotherapy, stereotactic body radiotherapy, brachytherapy
Summary
Sellar and skull base tumors encompass a biologically diverse spectrum, ranging from indolent lesions to invasive and clinically aggressive neoplasms with complex patterns of progression and recurrence. Despite advances in diagnosis and local management, major unmet needs remain in identifying actionable molecular targets, predicting treatment response, and overcoming treatment resistance. This Special Issue will highlight mechanistic and translational oncology studies focused on molecular drivers, tumor microenvironment and immune contexture, and biomarkers of aggressiveness, recurrence, and therapeutic response in sellar and skull base tumors, including pituitary neuroendocrine tumors (PitNETs), clival tumors, and metastatic lesions involving the skull base. Topics of interest include genetic and epigenetic alterations, endocrine-oncology signaling networks, invasion and adaptation to the skull base niche, and determinants of sensitivity or resistance to systemic therapies (e.g., temozolomide, targeted agents, and immunotherapies), including pathways related to DNA repair, MGMT, and mismatch repair. We particularly welcome submissions integrating clinically annotated biospecimens, liquid biomarkers, spatial or single-cell profiling, and patient-derived experimental models (primary cultures, organoids, xenografts) with functional or orthogonal validation. Clinically oriented studies are encouraged when they provide robust molecular characterization and validated translational insight, rather than descriptions of surgical or radiotherapy techniques. The goal is to accelerate precision oncology strategies for sellar and skull base neoplasms.
Keywords
sellar tumors, skull base tumors, pituitary neuroendocrine tumor (PitNET), clival tumors, chordoma, metastasis, tumor microenvironment, biomarkers, targeted therapy, immunotherapy, temozolomide, MGMT, mismatch repair, drug resistance, precision oncology, organoids, patient-derived models
Login
Register
Submit a Paper
Propose a Special lssue